TIAA CREF Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

TIAA CREF Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-76,640	Closed	-$658K	–	3109
2018 Q1	$658K	Buy	76,640 +44,106	+136%	+$831K	﹤0.01%	2628
2017 Q4	$677K	Buy	32,534 +9,026	+38%	+$160K	﹤0.01%	2647
2017 Q3	$415K	Buy	23,508 +136	+0.6%	+$1.88K	﹤0.01%	2912
2017 Q2	$264K	Buy	23,372 +3,812	+19%	+$40.8K	﹤0.01%	3057
2017 Q1	$251K	Sell	19,560 -3,358	-15%	-$54.1K	﹤0.01%	2959
2016 Q4	$504K	Buy	22,918 +12,825	+127%	+$286K	﹤0.01%	2847
2016 Q3	$213	Buy	+10,093	New	+$138K	﹤0.01%	3043

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TIAA CREF Investment Management's PTGX Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Protagonist Therapeutics (PTGX) in Q2 2018, closing a stake of 76,640 shares — an estimated $658K sold.

TIAA CREF Investment Management first reported a position in PTGX in Q3 2016 and held it in 7 quarters. The position peaked at $677K in Q4 2017. 69 funds tracked by Wall St. Rank hold PTGX as of Q2 2018.

TIAA CREF Investment Management reported no remaining Protagonist Therapeutics position as of Q2 2018 after selling out during the quarter.
TIAA CREF Investment Management sold 76,640 Protagonist Therapeutics shares in Q2 2018, an estimated $658K.
TIAA CREF Investment Management first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 7 quarters.
TIAA CREF Investment Management's Protagonist Therapeutics position peaked at $677K in Q4 2017.
69 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.